The US government's reappointment of Ogilvy & Mather to handle its $152 million anti-drug account has come under fire following allegations of billing irregularities on previous government business. Members of the US Senate and Congress, as well as losing agencies, have demanded that the billing problems, which have left the agency open to a continuing criminal investigation, should have precluded O&M from the pitch.
A new Campaign for a new breed
New ideas, new perspectives, new focus
Register for tailored email bulletins today and let us deliver the insight that you needRegister Now
Get the very latest news and insight from Campaign with unrestricted access to campaignlive.co.uk ,plus get exclusive discounts to Campaign eventsBecome a member